Wu Feng, Wang Zhi-Biao, Lu Pei, Xu Zhong-Li, Chen Wen-Zhi, Zhu Hui, Jin Cheng-Bing
Clinical Center for Tumor Therapy of 2(nd) Affiliated Hospital, and Institute of Ultrasonic Engineering in Medicine, Chongqing University of Medical Sciences, Chongqing, China.
Ultrasound Med Biol. 2004 Sep;30(9):1217-22. doi: 10.1016/j.ultrasmedbio.2004.08.003.
T cell-mediated immune responses represent the main cellular antitumor immunity in cancer patients. Recent studies have shown that that both surgical procedure and radiation therapy could cause the functional suppression of lymphocyte-mediated cellular immunity. The purpose of current study is to evaluate whether high intensity focused ultrasound (HIFU) might change a systemic antitumor immunity, particularly T lymphocyte-mediated immunity in cancer patients. A total of 16 patients with solid malignancies were treated with HIFU. Among them, six patients had osteosarcoma (Enneking stage, II(B)4, III(B) 2), five had hepatocellular carcinoma (TNM stage, III 3, IV 2), and five had renal cell carcinoma (TNM stage, III 2, IV 3). Using flow cytometry technique, T lymphocyte and subset, B lymphocyte and natural killer cell (NK) in the peripheral blood were measured in these patients on the day before HIFU and 7 to 10 d after HIFU. The statistical significance of any observed difference is evaluated by Student's t-test. The results showed a significance increase in the population of CD4(+) lymphocytes (p < 0.01) and the ratio of CD4(+) /CD8(+) (p < 0.05) in the circulation of cancer patients after HIFU treatment. The abnormal levels of CD3(+) lymphocytes returned toward the normal range in two patients, CD4(+)/CD8(+) ratio in 3, CD19(+) lymphocytes in one and cytotoxic NK in one, respectively, in comparison to control values. It is concluded that HIFU could enhance a systemic antitumor cellular immunity in addition to local tumor destruction in patients with solid malignancies.
T细胞介导的免疫反应是癌症患者主要的细胞抗肿瘤免疫。最近的研究表明，手术和放射治疗均可导致淋巴细胞介导的细胞免疫功能抑制。本研究的目的是评估高强度聚焦超声（HIFU）是否会改变癌症患者的全身抗肿瘤免疫，特别是T淋巴细胞介导的免疫。共有16例实体恶性肿瘤患者接受了HIFU治疗。其中，6例患有骨肉瘤（Enneking分期，II（B）4，III（B）2），5例患有肝细胞癌（TNM分期，III 3，IV 2），5例患有肾细胞癌（TNM分期，III 2，IV 3）。采用流式细胞术技术，在HIFU治疗前一天以及HIFU治疗后7至10天测量这些患者外周血中的T淋巴细胞及其亚群、B淋巴细胞和自然杀伤细胞（NK）。通过Student t检验评估任何观察到的差异的统计学意义。结果显示，HIFU治疗后癌症患者循环中CD4（+）淋巴细胞数量（p < 0.01）和CD4（+）/CD8（+）比值（p < 0.05）显著增加。与对照值相比，2例患者CD3（+）淋巴细胞的异常水平恢复至正常范围，3例患者CD4（+）/CD8（+）比值恢复正常，1例患者CD19（+）淋巴细胞恢复正常，1例细胞毒性NK恢复正常。结论是，HIFU除了能破坏实体恶性肿瘤患者的局部肿瘤外，还能增强全身抗肿瘤细胞免疫。
